Lyell Immunopharma, INC 8-K filings

Lyell Immunopharma announced second quarter 2026 financial results and business highlights, detailing advancements in its CAR T-cell therapies for LBCL and mCRC, with approximately $228 million in cash providing runway into Q3 2027.

Lyell Immunopharma, Inc. announced the results of its 2026 annual meeting of stockholders, including the election of Class II directors and the ratification of its independent auditor.

Lyell Immunopharma reported Q4 and full year 2025 financial results, highlighting significant clinical progress in its CAR T-cell therapy pipeline and an extended cash runway.

Lyell Immunopharma presented promising clinical and translational data for its CAR T-cell therapy ronde-cel in large B-cell lymphoma at the ASH Annual Meeting.

Lyell Immunopharma, Inc. announced amendments to its bylaws, effective immediately, modernizing stockholder proposal procedures and clarifying voting standards.

Lyell Immunopharma announced its third quarter 2025 financial results and significant progress in its CAR T-cell therapy pipeline, including new RMAT designations and clinical trial initiations.

Lyell Immunopharma has acquired exclusive global rights to LYL273, a novel CAR T-cell product candidate for metastatic colorectal cancer, showing promising early clinical results.

Lyell Immunopharma, Inc. announced the appointment of Lynn Seely, M.D. as interim principal financial officer and Veronica Sanchez Bulis as principal accounting officer.

Lyell Immunopharma announced the resignation of Chief Financial Officer Charles Newton, effective October 31, 2025, with a search for his replacement underway.

Lyell Immunopharma announced positive clinical data for LYL314 in LBCL, initiated a pivotal trial, and secured $100 million in private placement, extending its cash runway into mid-2027.

Lyell Immunopharma announced a private placement deal to raise up to $100 million, extending its cash runway into mid-2027 and funding pivotal clinical trials for its lead CAR T-cell therapy candidate, LYL314.

Lyell Immunopharma, Inc. announced the issuance of 625,000 common shares to ImmPACT Bio securityholders after a key clinical milestone for ImmPACT's next-generation CAR T-cell product candidate was achieved.

Lyell Immunopharma, Inc. announced new positive clinical data from its Phase 1/2 trial of LYL314, an autologous dual-targeting CD19/CD20 CAR T-cell product candidate, showing high response rates and a manageable safety profile in patients with large B-cell lymphoma.

Lyell Immunopharma, Inc. announced the expansion of its Board of Directors and the appointment of Dr. Mark Bachleda, Pharm.D., M.B.A., as a new Class I director, effective June 9, 2025.

Lyell Immunopharma, Inc. has filed a Certificate of Amendment to effect a 1-for-20 reverse stock split of its common stock, effective May 30, 2025, with trading on a split-adjusted basis commencing June 2, 2025.

Lyell Immunopharma held its 2025 annual meeting of stockholders, where key proposals including the election of a Class I director and a reverse stock split were approved.

Lyell Immunopharma announces positive clinical data for LYL314 and reports financial results for the first quarter of 2025, with a focus on advancing its CAR T-cell therapies.

Lyell Immunopharma is closing its West Hills manufacturing facility, reducing its workforce, and reiterating its expectation of sufficient cash runway into 2027.

Lyell Immunopharma announces promising clinical data for IMPT-314 and plans to initiate pivotal trials in 2025 and 2026, supported by a strong cash position.

Lyell Immunopharma has been notified by Nasdaq that its stock price has fallen below the minimum required bid price of $1.00 per share for continued listing.

Lyell Immunopharma finalized its acquisition of ImmPACT Bio, incorporating ImmPACT's cell therapy programs and technologies into its portfolio.

Lyell Immunopharma reported a 94% objective response rate and a 71% complete response rate in a Phase 1-2 trial of IMPT-314 for large B-cell lymphoma.

Hans Bishop resigned from Lyell Immunopharma's Board of Directors and Nominating and Corporate Governance Committee, effective November 22, 2024.

Lyell Immunopharma announced its third quarter 2024 financial results, highlighting the acquisition of ImmPACT Bio and progress in its clinical pipeline, including the advancement of IMPT-314 and LYL119.

Lyell Immunopharma has completed its acquisition of ImmPACT Bio, adding a promising dual-targeting CAR T-cell therapy to its pipeline and appointing ImmPACT's former CEO to its board.

Lyell Immunopharma will acquire ImmPACT Bio, adding a dual-targeting CAR T-cell therapy to its pipeline and focusing on next-generation CAR T-cell programs.

Lyell Immunopharma announced positive clinical trial results for its LYL797 cancer therapy and provided a financial update for the second quarter of 2024, highlighting a strong cash position.

Lyell Immunopharma announced positive initial clinical data from its Phase 1 trial of LYL797, a CAR T-cell therapy, showing dose-dependent anti-tumor activity and tumor infiltration in patients with advanced solid tumors.

Lyell Immunopharma held its 2024 annual meeting, electing two Class III directors and ratifying Ernst & Young LLP as its independent auditor.

Lyell Immunopharma announced its first quarter 2024 financial results, highlighting progress in its clinical programs and a strong cash position to support operations into 2027.